Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 21;85(16):3041-3056.e9.
doi: 10.1016/j.molcel.2025.06.026. Epub 2025 Jul 21.

β-catenin functions as a molecular adapter for disordered cBAF interactions

Affiliations

β-catenin functions as a molecular adapter for disordered cBAF interactions

Yuen San Chan et al. Mol Cell. .

Abstract

BAF (SWI/SNF) chromatin remodelers engage binding partners to generate site-specific DNA accessibility. However, the basis for interaction between BAF and divergent binding partners has remained unclear. Here, we tested the hypothesis that scaffold proteins augment BAF's binding repertoire by examining β-catenin (CTNNB1) and steroidogenic factor 1 (SF-1, NR5A1), a transcription factor central to steroid production in human cells. BAF inhibition rapidly opposed SF-1/β-catenin enhancer occupancy, impairing SF-1 target activation and SF-1/β-catenin autoregulation. These effects arise due to β-catenin's role as a molecular adapter between SF-1 and an intrinsically disordered region (IDR) of the canonical BAF (cBAF) subunit ARID1A. In contrast to exclusively IDR-driven mechanisms, adapter function is mediated by direct association of ARID1A with β-catenin's folded Armadillo repeats. β-catenin similarly linked cBAF to YAP1, SOX2, FOXO3, and CBP/p300, reflecting a general IDR-mediated mechanism for modular coordination between factors. Molecular visualization highlights β-catenin's adapter role for interaction of cBAF with binding partners.

Keywords: IDRs; adrenocortical carcinoma; chromatin remodeling; co-activators; scaffold proteins; steroid hormones; transcription factors; transcription regulators; unstructured protein.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests G.D.H. reports unrelated personal fees from Radionetics and Orphagen Pharmaceuticals for consultation on projects outside the scope of this work.

References

    1. Cermakova K, Tao L, Dejmek M, Sala M, Montierth MD, Chan YS, Patel I, Chambers C, Loeza Cabrera M, Hoffman D, et al. (2023). Reactivation of the G1 enhancer landscape underlies core circuitry addiction to SWI/SNF. Nucleic Acids Res. 10.1093/nar/gkad1081. - DOI - PMC - PubMed
    1. Chambers C, Cermakova K, Chan YS, Kurtz K, Wohlan K, Lewis AH, Wang C, Pham A, Dejmek M, Sala M, et al. (2023). SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia. Cancer Res 83, 983–996. 10.1158/0008-5472.CAN-22-2129. - DOI - PMC - PubMed
    1. Hodges HC, Stanton BZ, Cermakova K, Chang C-Y, Miller EL, Kirkland JG, Ku WL, Veverka V, Zhao K, and Crabtree GR (2018). Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers. Nat Struct Mol Biol 25, 61–72. 10.1038/s41594-017-0007-3. - DOI - PMC - PubMed
    1. Stanton BZ, Hodges C, Calarco JP, Braun SMG, Ku WL, Kadoch C, Zhao K, and Crabtree GR (2017). Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin. Nat Genet. 10.1038/ng.3735. - DOI - PMC - PubMed
    1. Kadoch C, Williams RT, Calarco JP, Miller EL, Weber CM, Braun SMG, Pulice JL, Chory EJ, and Crabtree GR (2017). Dynamics of BAF–Polycomb complex opposition on heterochromatin in normal and oncogenic states. Nat Genet 49, 213–222. 10.1038/ng.3734. - DOI - PMC - PubMed

MeSH terms